# Key References

Literature supporting the VDAC1 Gate-Opening Therapeutic Stack.

Two source documents:
- **SAD v4.0** -- Strategic Architecture Document citations (~30 references)
- **VDAC1 Pharmacology Atlas** -- Companion bibliography (78 references, `VDAC1_Pharmacology_Atlas_Works_Cited.docx`)

Combined unique references: **~90**. Organized below by GJS equation term and mechanistic layer.

---

## VDAC1 Structural Biology (The Protein)

| # | Citation | Finding | GJS Relevance |
|---|----------|---------|---------------|
| 1 | **Bayrhuber et al.** *PNAS* (2008) | Human VDAC1 structure | Channel architecture |
| 2 | **Ujwal et al.** *PNAS* (2008) | Mouse VDAC1 crystal structure at 2.3 A, metabolite gating | Gate mechanics |
| 3 | **Hiller et al.** *Science* (2008) | Solution NMR structure of human VDAC1 | Channel conformation |
| 5 | **Najbauer et al.** *PNAS* (2024) | Room-temperature VDAC1 by solid-state NMR + cryo-EM | Current structural state |
| 6 | **Hosaka et al.** *Nat Struct Mol Biol* (2025) | Cryo-EM of VDAC1 oligomer: N-terminal helix extrusion during apoptosis | **Direct oligomer structure** |

## VDAC1 Electrophysiology and Gating

| # | Citation | Finding |
|---|----------|---------|
| 7 | **Colombini** *Mol Cell Biochem* (2004) | VDAC as interface channel between mitochondria and cytosol |
| 8 | **Colombini** *BBA Biomembranes* (2012) | VDAC structure, selectivity, and dynamics |
| 9 | **Rostovtseva & Bhatt** *Int J Mol Sci* (2015) | Electrophysiological insights into VDAC gating |

## VDAC1 Oligomerization and Pore Formation

| # | Citation | Finding | GJS Relevance |
|---|----------|---------|---------------|
| 11 | **Keinan et al.** *Prog Mol Biol Transl Sci* (2010) | VDAC1 oligomerization: structure to function and cancer therapy | Gate-opening class |
| 12 | **Zalk et al.** *Biochem J* (2005) | Oligomeric states and cytochrome c release | Pore physics |
| 13 | **Bayrhuber et al.** *Nat Commun* (2023) | VDAC forms phospholipid scramblase dimers at OMM | Oligomer function |
| 33 | **Kim et al.** *Science* (2019) | VDAC oligomers form pores releasing mtDNA fragments (500-650 bp) | **Core gate physics** |
| 54 | **Geula et al.** *J Biol Chem* (2012) | Structure-based analysis of VDAC1 oligomer contact sites | Oligomer interface |

## Lipid Annulus, Cholesterol, and Honeycomb Arrays ([Chol]/[CL] term)

| # | Citation | Finding | GJS Relevance |
|---|----------|---------|---------------|
| 15 | **Budelier et al.** *J Biol Chem* (2017) | Photoaffinity-mapped cholesterol binding site on VDAC1 | **Direct structural evidence for lipid annulus** |
| 17 | **Gonzalez-Morales et al.** *J Mol Biol* (2023) | AFM reveals VDAC1 honeycomb arrays in native membranes | Lattice visualization |
| -- | **Montero et al.** *Cancer Research* (2008) | Elevated mitochondrial cholesterol confers chemotherapy resistance | Cholesterol lock |
| -- | **Shen et al.** *eLife* (2024) | Statins specifically reduce mitochondrial membrane cholesterol | Lovastatin mechanism |
| -- | **Betaneli et al.** *Biophysical J* (2012) | Cholesterol rigidifies OMM, disfavors VDAC1 oligomeric transitions | Membrane physics |
| -- | **Huang et al.** *Antioxidants* (2024) | Lovastatin induces mtDNA release + cGAS-STING in HCT116 | **Core mechanism** |

## Hexokinase-II / VDAC Interactions (f_HKII term -- Lock 1)

| # | Citation | Finding | GJS Relevance |
|---|----------|---------|---------------|
| 18 | **Pastorino & Hoek** *J Bioenerg Biomembr* (2008) | Regulation of hexokinase binding to VDAC | HK-II lock mechanism |
| 19 | **Pastorino et al.** *J Biol Chem* (2002) | HK-II binding inhibits Bax-induced cytochrome c release | Anti-apoptotic function |
| 20 | **Mathupala et al.** *Oncogene* (2006) | HK-II as cancer's double-edged sword at mitochondria | Warburg/gate-jamming |
| 21 | **Abu-Hamad et al.** *J Biol Chem* (2008) | HK-I protection via VDAC1 interaction | Lock 1 specificity |

## Bcl-2 Family / VDAC Interactions (f_BclxL term -- Lock 2)

| # | Citation | Finding | GJS Relevance |
|---|----------|---------|---------------|
| 22 | **Arbel et al.** *J Biol Chem* (2012) | Bcl-xL anti-apoptotic activity mediated by VDAC1 interaction | **Lock 2 mechanism** |
| 23 | **Shimizu et al.** *Nature* (1999) | Bcl-2 family regulates cytochrome c release through VDAC | Bcl-2/VDAC axis |
| 24 | **Chipuk et al.** *Mol Cell* (2010) | BCL-2 family reunion: complete regulatory network | Family context |
| 56 | **Oltersdorf et al.** *Nature* (2005) | Bcl-2 family inhibitor induces regression of solid tumors | Venetoclax precedent |

## Cardiolipin Biology ([CL] denominator)

| # | Citation | Finding | GJS Relevance |
|---|----------|---------|---------------|
| 25 | **Kagan et al.** *Nat Chem Biol* (2005) | Cytochrome c as cardiolipin oxygenase in apoptosis | CL oxidation |
| 26 | **Chu et al.** *Nat Cell Biol* (2013) | CL externalization as mitophagy elimination signal | CL dynamics |
| 27 | **Schlattner et al.** *BBA Biomembranes* (2009) | Mitochondrial kinases and cardiolipin interactions | CL regulatory network |

## cGAS-STING Pathway (Innate Immune Ignition)

| # | Citation | Finding | GJS Relevance |
|---|----------|---------|---------------|
| 34 | **West et al.** *Nature* (2015) | mtDNA stress primes antiviral innate immune response | mtDNA as STING ligand |
| -- | **Li & Chen** (2018) | cGAS-STING: cytosolic DNA sensing to type I interferon | Pathway mechanics |

## Clinical Validation: Statin + ICI

| Citation | Finding | Evidence Grade |
|----------|---------|---------------|
| **Liao et al.** *JCO Oncology Practice* (2025) | Meta-analysis (n=46,154): statin + ICI = 20% mortality reduction | Strong (meta) |
| **Stokes et al.** *J ImmunoTherapy of Cancer* (2023) | Statins enhance PD-1 blockade via M2-to-M1 repolarization | Strong |
| **Tan & Bhatt** *Int J Cancer* (2015) | Statin use and HCC risk: systematic review and meta-analysis | Supporting |

## Cavalry Drug: Botensilimab

| Citation | Finding | Evidence Grade |
|----------|---------|---------------|
| **Vidal et al.** *Nature Medicine* (2024) | Botensilimab + balstilimab: 17-20% ORR in MSS CRC | Moderate (Phase I) |

## TSPO / Fourth Lock (Exploratory)

| Citation | Finding | Relevance |
|----------|---------|-----------|
| **Gatliff et al.** *Autophagy* (2014) | TSPO physically binds VDAC1 on OMM | Fourth lock candidate |
| **Maaser et al.** *Clin Cancer Res* (2002/2005) | TSPO overexpression in 28% CRC; prognostic | Biomarker |
| **Banati et al.** *Nat Commun* (2014) | TSPO-KO mice viable, normal lifespan | Safety |
| **Zhang et al.** *Advanced Science* (2023) | PK11195 + anti-PD-1 synergy in HCC | Combination |
| **Tu et al.** *Endocrinology* (2015) | PK11195 off-target effects in TSPO-KO | Selectivity caution |
| **Fu et al.** *Neuro-Oncology* (2020) | TSPO-KD promotes glioblastoma growth | Directionality caution |

## CBD / Cannabinoid Pharmacology (Quarantine Evidence)

| # | Citation | Finding | Relevance |
|---|----------|---------|-----------|
| 35 | **Rimmerman et al.** *Cell Death Dis* (2013) | CBD directly modulates VDAC1 on OMM | **Direct VDAC1 binding** |
| 36 | **Olivas-Aguirre et al.** *Cell Death Dis* (2019) | CBD targets mitochondria, disturbs calcium in ALL | Mitochondrial mechanism |
| 37 | **Mahmoud & Bhatt** *JPET* (2023) | CBD modulates mitochondrial membrane potential via VDAC1 | VDAC1 specificity |
| 40 | **Massi et al.** *Br J Clin Pharmacol* (2013) | CBD as potential anticancer drug | Preclinical review |
| 41 | **Ligresti et al.** *JPET* (2006) | Antitumor activity of plant cannabinoids in breast carcinoma | CBD efficacy |
| -- | **Sido et al.** (2016) | CBD suppresses CD8+ T-cell proliferation at 5-10 uM | Quarantine Basis 1 |
| -- | **Kaplan et al.** (2003) | CBD immunosuppressive at VDAC1-active concentrations | Quarantine Basis 1 |
| -- | **Nelson et al.** *J Med Chem* (2020) | CBD colloidal aggregation at >10 uM | Specificity concern |
| -- | **Bar-Sela et al.** | Cannabis users: OS 6.4 vs 28.5 months on immunotherapy | Clinical signal |
| -- | **Catherall et al.** *MCP* (2022) | Cholesterol disruption potentiates CBD-induced apoptosis | Possible late-stage role |

## Erastin, Ferroptosis, and Alternative VDAC-Dependent Cell Death

| # | Citation | Finding | Relevance |
|---|----------|---------|-----------|
| 42 | **Yagoda et al.** *Nature* (2007) | RAS-RAF-MEK oxidative cell death involving VDAC | VDAC-dependent death |
| 43 | **Dixon et al.** *Cell* (2012) | Ferroptosis: iron-dependent non-apoptotic cell death | Alternative pathway |
| 51 | **Maldonado et al.** *J Biol Chem* (2013) | VDAC modulates cancer cell metabolism; erastin regulation | VDAC pharmacology |

## Warburg Effect and Cancer Metabolism

| # | Citation | Finding |
|---|----------|---------|
| 48 | **Warburg** *Science* (1956) | On the origin of cancer cells |
| 49 | **Vander Heiden et al.** *Science* (2009) | Understanding the Warburg effect: metabolic requirements of proliferation |
| 50 | **Pedersen** *J Bioenerg Biomembr* (2007) | Warburg, HK-II, and cancer's most common phenotype |

## VDAC Pore Blockers and Drug Candidates

| # | Citation | Finding | Relevance |
|---|----------|---------|-----------|
| 44 | **Shoshan-Barmatz et al.** *Mol Aspects Med* (2010) | VDAC1 regulating cell life and death: pharmacological target | Comprehensive review |
| 45 | **Shoshan-Barmatz & Ben-Hail** *Mitochondrion* (2012) | VDAC as pharmacological target | Drug development |
| 46 | **Bordet et al.** *JPET* (2007) | Olesoxime (cholest-4-en-3-one oxime): cholesterol-based VDAC ligand | Lipid annulus pharmacology |
| 53 | **Shteinfer-Kuzmine et al.** *Mol Oncol* (2018) | VDAC1-based peptides for selective cancer cell death | Peptide therapeutics |

## Apoptosis and Cell Death (Framework)

| # | Citation | Finding |
|---|----------|---------|
| 31 | **Galluzzi et al.** *Cell Death Differ* (2018) | Molecular mechanisms of cell death (Nomenclature Committee) |
| 32 | **Tait & Green** *Nat Rev Mol Cell Biol* (2010) | Mitochondria and cell death: OMM permeabilization |
| 76 | **Green & Llambi** *Cold Spring Harb Perspect Biol* (2015) | Cell death signaling |
| 77 | **Kroemer et al.** *Physiol Rev* (2007) | Mitochondrial membrane permeabilization in cell death |

## Falsification Sources (Killed Original Hypothesis)

| Citation | What It Killed | Implication |
|----------|---------------|-------------|
| **Jimenez-Loygorri et al.** *Nat Commun* (2024) | TSPO-mitophagy-mtDNA pathway | Mitophagy clears mtDNA, doesn't release it |
| **Bakhoum et al.** *Cancer Discovery* (2020) | Chronic cGAS-STING as therapeutic | Chronic activation is immunosuppressive |
| **Sliter et al.** (2018) | Mitophagy as mtDNA release mechanism | Clearance, not release |
| **Wang et al.** *Autophagy* (2025) | Mitophagy dynamics | Confirms clearance role |

## Comprehensive VDAC Reviews

| # | Citation | Scope |
|---|----------|-------|
| 72 | **Shoshan-Barmatz et al.** *Cell Stress* (2017) | VDAC1 at crossroads of metabolism, apoptosis, stress |
| 73 | **Camara et al.** *Front Physiol* (2017) | VDAC1 as therapeutic target |
| 74 | **Lemasters** *BBA Mol Basis Dis* (2007) | VDAC as mitochondrial governator |
| 75 | **Szabo** *Physiol Rev* (2010) | Mitochondrial channels: ion fluxes and more |

## Self-Citation

| # | Citation | Note |
|---|----------|------|
| 69 | **Vasquez & Claude Opus 4.6** *OSF Preprints* (2026) | CBD paradox at the mitochondrial gate: multi-LLM convergence study. DOI: 10.17605/OSF.IO/NUXHV |

---

*Combined unique citations: ~90 | Sources: SAD v4.0 + VDAC1 Pharmacology Atlas*
*Full bibliography with complete citation details: `VDAC1_Pharmacology_Atlas_Works_Cited.docx`*
